Jump to content
Admin

Study Supports Patient-reported Tool Measuring Fatigue’s Impact on Daily Activities

Recommended Posts

The findings were presented at the recent 2019 American College of Rheumatology/Association for Rheumatology Professionals Annual Meeting in a session, titled “Assessment of Fatigue in Adults with Moderate to Severe Systemic Lupus Erythematosus (SLE): A Qualitative Study to Explore What Patients Feel Should Be Measured in Clinical Trials.”

Fatigue has a well-known impact on people with SLE, but it has not been measured using self-reported feedback from patients, which poses a challenge for assessing the symptom in clinical studies.

To address this gap, a team at Evidera, Idorsia Pharmaceuticals, Stanford University, and the Lupus Foundation of America studied how people with SLE view their fatigue and whether it could be assessed with the FACIT-F (Functional Assessment of Chronic Illness Therapy-Fatigue) questionnaire, which has been used in medical research.

The study involved 28 adults with moderate to severe SLE (27 women, mean age of 45.5 years). The researchers first conducted focus groups, then 13 one-on-one interviews. Both rounds focused on the role of SLE-related fatigue in participants’ daily lives and their opinions on FACIT-F.

Twenty-three patients (82%) had moderate disease activity and five (18%) had severe SLE. All were being treated for SLE during the study.

Results showed that 23 participants (82%) identified fatigue as one of the top three most impactful symptoms of SLE. They said that fatigue had a profound impact on daily life, “including the ability to perform chores, work-related activities, maintain personal hygiene, exercise, and participate in hobbies,” the researchers wrote.

FACIT-F was generally viewed as a satisfactory tool by the participants, who said that they were able to understand the questionnaire, and it was relevant to their experience of fatigue.

Overall, the study confirmed the significant impact of fatigue in the life of people with SLE and showed that it can be measured using FACIT-F.

The tool is being used by Idorsia in its CARE Phase 2b clinical trial (NCT03742037) of the potential oral therapy cenerimod. This international study is still enrolling adults with SLE; more information about contacts and locations is available here.

 
 
Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
 
 
José is a science news writer with a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimer’s disease.
 

Share this post


Link to post
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...

×
×
  • Create New...

Important Information